Mr Learner, I respect your opinion and from what you have posted you appear to have been through some challenging personal health issues that may have first piqued your interest in Imugene, however I cannot agree with your first statement.
I believe for a start that many that have realised large losses with IMU will be running for the hills from any biotech company regardless of medium term promise.
Also with a brief search of Australian small cap biotechs in the cancer space that are not income producing it is clear many of them are well down from their 12 month highs.
The shareholders left on the registry following the consolidation will probably be in 3 camps. 1. The rusted on shareholder that believes in the science and Management of the company and feel results thus far warrant sticking around. 2. Those that are down 90%+ that believe their money is gone, but also hold out the faintest hope that things will turn around with the release of good data or a partnership/lisencing deal. 3. Those that believe a bit of 1 and 2.
For disclosure I'm in the first cohort.
DYOR opinion only
IMU Price at posting:
1.6¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)